Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Operations: 2010-2025

Historic Cash from Operations for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to $6.9 million.

  • Anika Therapeutics' Cash from Operations rose 36.96% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 9.04%. This contributed to the annual value of $5.4 million for FY2024, which is 402.18% up from last year.
  • Anika Therapeutics' Cash from Operations amounted to $6.9 million in Q3 2025, which was up 3,734.92% from -$189,000 recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Cash from Operations peaked at $6.9 million during Q3 2025, and registered a low of -$8.3 million during Q2 2023.
  • For the 3-year period, Anika Therapeutics' Cash from Operations averaged around $924,182, with its median value being -$126,000 (2024).
  • Data for Anika Therapeutics' Cash from Operations shows a peak YoY increase of 656.34% (in 2023) and a maximum YoY decrease of 368.56% (in 2023) over the last 5 years.
  • Anika Therapeutics' Cash from Operations (Quarterly) stood at $4.5 million in 2021, then crashed by 89.24% to $481,000 in 2022, then skyrocketed by 656.34% to $3.6 million in 2023, then tumbled by 56.51% to $1.6 million in 2024, then skyrocketed by 36.96% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, -$189,000 for Q2 2025, and -$130,000 during Q1 2025.